4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.88 Average PT from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $30.6667.

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. B. Riley Financial began coverage on shares of 4D Molecular Therapeutics in a research report on Friday. They set a “buy” rating and a $37.00 target price for the company. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $10.09 on Thursday. 4D Molecular Therapeutics has a fifty-two week low of $5.11 and a fifty-two week high of $14.00. The business’s 50-day moving average is $10.61 and its two-hundred day moving average is $9.68. The company has a market cap of $527.51 million, a price-to-earnings ratio of -3.93 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Equities analysts predict that 4D Molecular Therapeutics will post -3.81 earnings per share for the current year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider David Kirn sold 114,746 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider owned 942,485 shares of the company’s stock, valued at $9,867,817.95. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. The trade was a 53.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 184,811 shares of company stock worth $2,075,906 over the last quarter. 7.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FDMT. Bank of America Corp DE lifted its holdings in 4D Molecular Therapeutics by 17.0% during the first quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock valued at $9,070,000 after purchasing an additional 141,582 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after purchasing an additional 611,276 shares in the last quarter. Exome Asset Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the first quarter worth $1,216,000. Renaissance Technologies LLC raised its position in shares of 4D Molecular Therapeutics by 12.7% during the 1st quarter. Renaissance Technologies LLC now owns 578,265 shares of the company’s stock valued at $5,384,000 after purchasing an additional 65,365 shares during the period. Finally, Sei Investments Co. lifted its stake in shares of 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after buying an additional 1,050 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.